|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0013216,
umls-concept:C0015133,
umls-concept:C0123931,
umls-concept:C0205263,
umls-concept:C0205420,
umls-concept:C0282460,
umls-concept:C0332283,
umls-concept:C0684249,
umls-concept:C0817096,
umls-concept:C1522449
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2005-5-23
|
|
pubmed:abstractText |
Irinotecan plus cisplatin (IP) chemotherapy demonstrated a promising outcome with a high complete response (CR) rate in chemotherapy-naïve patients with extensive small-cell lung cancer (SCLC). We evaluated the efficacy of induction IP chemotherapy followed by concurrent etoposide plus cisplatin (EP) chemotherapy with twice-daily thoracic radiotherapy (TDTRT) in limited-disease SCLC (LD-SCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3488-94
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15908658-Adult,
pubmed-meshheading:15908658-Aged,
pubmed-meshheading:15908658-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15908658-Camptothecin,
pubmed-meshheading:15908658-Carcinoma, Small Cell,
pubmed-meshheading:15908658-Cisplatin,
pubmed-meshheading:15908658-Combined Modality Therapy,
pubmed-meshheading:15908658-Cranial Irradiation,
pubmed-meshheading:15908658-Dose-Response Relationship, Radiation,
pubmed-meshheading:15908658-Etoposide,
pubmed-meshheading:15908658-Female,
pubmed-meshheading:15908658-Follow-Up Studies,
pubmed-meshheading:15908658-Humans,
pubmed-meshheading:15908658-Lung Neoplasms,
pubmed-meshheading:15908658-Male,
pubmed-meshheading:15908658-Middle Aged,
pubmed-meshheading:15908658-Neoplasm Staging,
pubmed-meshheading:15908658-Radiotherapy, Adjuvant,
pubmed-meshheading:15908658-Radiotherapy Dosage,
pubmed-meshheading:15908658-Remission Induction,
pubmed-meshheading:15908658-Risk Assessment,
pubmed-meshheading:15908658-Survival Analysis,
pubmed-meshheading:15908658-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
|
|
pubmed:affiliation |
Research Institute & Hospital, National Cancer Center, Goyang, Gyeonggi, Korea.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
